Compartmentalized Immune Engagement Without Effector Conversion in Immune-Tolerant Chronic Hepatitis B: A Donor-Level Tissue-Separated Single-Cell Reanalysis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background This is Zenodo version 2.0 of the ITLAS HBV immune-tolerant phase reanalysis, corresponding to analysis version V19. This record supersedes the previous V18-v2 release under the same Zenodo version chain. This study is a donor-level, tissue-separated single-cell transcriptomic reanalysis of GSE182159 originally published by Zhang et al. (Gut, 2023). The dataset comprises approximately 243,000 immune cells from 23 donors, including normal controls (NL), immune-tolerant chronic hepatitis B (IT), immune-active chronic hepatitis B (IA), chronic resolved (CR), and an independent acute resolved (AR) comparator cohort. The analysis tests whether the immune-tolerant phase is transcriptionally quiescent or instead shows immune engagement without canonical effector conversion. The findings are presented as hypothesis-generating observations consistent with effector restraint and require future functional and protein-level validation. Key features of V19 Donor-level and tissue-separated framework.All comparisons were performed at the patient level, with cell-level expression aggregated to donor-level values. Liver and blood compartments were analyzed separately to avoid tissue-composition artifacts. Multiple-testing correction used stratified Benjamini–Hochberg FDR, with the primary Level B stratum defined as comparison × tissue × lineage. Tier 1 / Tier 2 evidence reporting.Findings are explicitly classified by evidence strength. Tier 1 denotes findings surviving stratified BH FDR correction at q < 0.10. Tier 2 denotes nominal p < 0.05 with donor-pair consistency ≥80% but without FDR survival. All reported gene-level findings in V19 are Tier 2; Tier 1 designation is reserved for pathway-level findings that survive FDR correction. Six concurrent transcriptomic patterns.V19 prioritizes six transcriptomic patterns consistent with effector restraint in the IT phase:P1, myeloid immunoregulatory programming;P2, epigenetic-regulator upregulation;P3, metabolic–effector dissociation;P4, JAK1–SOCS discordance;P5, liver-dominant T-cell exhaustion programming; andP6, impaired terminal differentiation signature. Of 33 prioritized gene–lineage–tissue combinations, 32 were classified as ROBUST or VALID by Oaxaca–Blinder decomposition, supporting predominantly per-cell rather than composition-driven effects. BCR/TCR repertoire integration.V19 includes donor-level BCR/TCR repertoire analysis using patient-ID grouping. The IT phase showed a BCR-dominant pattern characterized by class-switching features and minimal non-singleton emergence, consistent with a “switched but not productively expanded” BCR phenotype. TCR clonality did not show significant NL→IT expansion. Hypothesis-generating interpretation.All gene- and pattern-level claims are framed as transcriptomic observations consistent with effector restraint. The study does not claim causal mechanism, antigen specificity, or functional validation. Methods summary The analysis used donor-level Mann–Whitney U testing with stratified Benjamini–Hochberg FDR correction. Six major immune lineages were analyzed across two tissue compartments; γδ T cells were excluded due to insufficient representation. Pathway scoring used AUCell-based gene-set scoring. Gene-to-gene correlation analysis used donor-level Spearman correlations, with the Figure 4 display network restricted to strong correlations, |ρ| ≥ 0.7, and stratified BH q < 0.10. Data and code Source dataset: NCBI GEO GSE182159Original study: Zhang et al., Gut, 2023Code, notebooks, and intermediate outputs: https://github.com/choccoba/ITLAS Status This is a computational reanalysis. The results should be interpreted as hypothesis-generating. Functional assays, protein-level validation, antigen-specific receptor analysis, and independent cohort validation are not included in this release and will be required to confirm the proposed biological patterns. Relationship to previous version V19 / Zenodo version 2.0 supersedes V18-v2 / Zenodo version 1.x. Substantive revisions include: refined Tier 1 / Tier 2 evidence framework; donor-level BCR/TCR repertoire recalculation using patient-collapsed grouping; correction of repertoire metric definitions, including clone-level singleton reporting; clearer separation of gene-level nominal findings from FDR-surviving pathway-level findings; revised tissue-separated visualization and statistical reporting; more conservative “consistent with effector restraint” language throughout. The previous version remains accessible through its version-specific Zenodo DOI for citation continuity. Readers should cite V19 / Zenodo version 2.0 for the current results. Version 2.0 patch (10.5281/zenodo.20037896; 2026-05-05): corrected page-orientation rendering for Tables 2 and 3 (landscape sections); embedded all main and supplementary figures into the manuscript PDF for reader convenience. No changes to scientific content, numerical values, or analytical results from the v2.0 (10.5281/zenodo.20034593).
Fields of Study & Subjects
Hepatitis B Virus Studies
Hepatitis C virus research
Liver physiology and pathology
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 March 2026
- Language
- EN
- Document type
- Preprint